Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aeterna Zentaris (AEZS)
Aeterna Zentaris (AEZS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,683
  • Shares Outstanding, K 4,856
  • Annual Sales, $ 5,640 K
  • Annual Income, $ -22,730 K
  • 60-Month Beta 1.63
  • Price/Sales 2.06
  • Price/Cash Flow N/A
  • Price/Book 0.44
Trade AEZS with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 73.99%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.97
  • Number of Estimates 1
  • High Estimate -0.97
  • Low Estimate -0.97
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -15.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +51.72%
on 11/15/23
2.42 -8.92%
on 12/08/23
+0.70 (+46.30%)
since 11/08/23
3-Month
1.36 +61.75%
on 11/01/23
2.74 -19.71%
on 09/12/23
-0.28 (-11.29%)
since 09/08/23
52-Week
1.36 +61.75%
on 11/01/23
4.00 -45.00%
on 12/09/22
-1.67 (-43.15%)
since 12/08/22

Most Recent Stories

More News
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PRTA : 36.08 (-4.55%)
AEZS : 2.20 (-7.95%)
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.

NVO : 96.64 (-0.18%)
AEZS : 2.20 (-7.95%)
ACAD : 20.98 (-3.72%)
APTX : 0.0620 (unch)
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AEZS : 2.20 (-7.95%)
ICVX : 10.51 (+4.79%)
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

CLSD : 1.0900 (-6.03%)
AEZS : 2.20 (-7.95%)
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

INBX : 24.97 (-1.54%)
AEZS : 2.20 (-7.95%)
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.

IDXX : 531.35 (+1.58%)
AEZS : 2.20 (-7.95%)
Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

JNJ : 154.42 (-0.63%)
ALKS : 25.86 (-1.15%)
AEZS : 2.20 (-7.95%)
RCUS : 15.77 (+0.83%)
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases

Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.

AZN : 63.25 (-0.41%)
IRWD : 10.48 (+0.77%)
AEZS : 2.20 (-7.95%)
ABBV : 149.28 (+0.89%)
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

AEZS : 2.20 (-7.95%)
IDXX : 531.35 (+1.58%)
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AEZS : 2.20 (-7.95%)
HALO : 39.95 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead...

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.51
1st Resistance Point 2.35
Last Price 2.20
1st Support Level 2.11
2nd Support Level 2.02
3rd Support Level 1.86

See More

52-Week High 4.00
Fibonacci 61.8% 2.99
Fibonacci 50% 2.68
Fibonacci 38.2% 2.37
Last Price 2.20
52-Week Low 1.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar